



AN ISO 9001 & A WHO GMP CERTIFIED COMPANY



To,

Date: 14.02.2022

1. Department of Corporate Services BSE Limited P.J. Towers, Dalal Street, Mumbai-400 001	2. National Stock Exchange of India Limited Exchange plaza, C-1, Block G, Bandra Kurla Complex, Bandra, East, Mumbai, MH 400 051
--	--

Dear Sir/Madam,

Sub: Outcome of Board Meeting held on 14.02.2022

Ref: Company's letter dated 31.01.2022

With reference to the subject cited, this is to inform the Exchange that at the meeting of the Board of Directors of Ortin Laboratories Limited held on Monday, 14.02.2022 at 4:00 p.m. at D.NO.1-8-84, Ground Floor, F3 HIG, Block-4, Street No.3 Baghlingampally, Hyderabad-500044, Telangana. The following were considered and approved:


1. Unaudited financial results for the quarter ended 31.12.2021. **(Enclosed)**
2. Limited Review Report as per Regulation 33 of SEBI (LO&DR) Regulations, 2015 for the quarter ended 31.12.2021. **(Enclosed)**
3. Shifting of Registered Office from D. No: 3-4-512/35 (43/4RT), OppBarkatpura Park, Barkatpura,Hyderabad-500027, Telangana to D.NO.1-8-B4,Ground Floor, F3 HIG,Block-4,Street No.3, Baghlingampally, Hyderabad-500044,Telangana w.e.f 14.02.2022.

The meeting concluded at **4:45 P.M.**

This is for the information and records of the Exchange.

Thanking you.

Yours sincerely,
For Ortin Laboratories Limited


S. Balaji Venkateswarlu
Director
DIN: 02010148
Encl: as above





AN ISO 9001 & A WHO GMP CERTIFIED COMPANY



Un-Audited Financial Results for the Quarter and Nine Months Ended Dec. 31, 2021

Rs. In Lakhs

S No	Particulars	Quarter Ended				Nine Months Ended		Year ended
		Dec. 31 2021	Sep. 30 2021	Jun. 30 2021	Dec. 31 2020	Dec. 31 2021	Dec. 31 2020	Mar.31, 2021
		Un Audited	Un Audited	Un Audited	Un Audited	Un Audited	Un Audited	Audited
1	Income							
	a) Revenue from Operations	165.86	229.37	198.44	5177.21	593.67	20701.11	816.74
	Total Revenue from operations	165.86	229.37	198.44	5177.21	593.67	20701.11	816.74
	b) Other Income	0.00	3.65	0.04	11.67	3.69	32.07	5.01
	Net Profit before tax (after Exceptional and/or Extraordinary items)	165.86	233.02	198.48	5188.88	597.36	20733.18	821.75
2	Expenses							
	a) Cost of materials Consumed	115.22	111.96	116.39	4641.57	343.56	16530.93	407.82
	b) Changes in inventories	-15.00	9.88	-8.25	-688.69	-13.37	525.86	(12.80)
	c) Employee benefits expense	23.20	24.52	22.63	182.58	70.35	490.16	105.22
	d) Finance costs	19.46	19.24	18.00	86.04	56.70	261.75	87.35
	e) Depreciation and amortization expense	-6.99	6.90	6.75	53.24	6.66	154.76	28.54
	f) Other expenses	41.04	53.86	31.21	825.53	126.11	2401.69	191.98
	Total Expenses (a to f)	176.93	226.36	186.72	5100.27	590.01	20365.15	808.11
3	Profit before tax (1-2)	(11.06)	6.66	11.76	88.61	7.35	368.03	13.65
4	Tax expenses							
	- Income Tax	-2.88	1.73	3.06	19.08	1.91	90.54	5.70
	- Deferred Tax	0.83	(0.45)	(0.41)	9.98	-0.02	-11.75	(86.60)
5	Net Profit for the period (3-4)	-9.03	5.38	9.11	59.55	5.46	289.24	94.55
6	Other comprehensive income							
	a) (i) Items that will not be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	(ii) Income tax relating to items that will not be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	b) (i) Items that will be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	(ii) Income tax relating to items that will be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	Total other comprehensive income	0.00	0.00	0.00	0.00	0.00	0.00	0.00
7	Total Comprehensive income (5 +6)	(9.03)	5.38	9.11	59.55	5.46	289.24	94.55
8	Paid-up Equity Share Capital (Rs.10/- per Equity Share)	813.14	813.14	813.14	1694.04	813.14	1694.04	813.14
9	Other Equity							322.41
10	Earnings per share (Face Value of Rs.10/- each)							
	(a) Basic (In Rs.)	-0.11	0.07	0.11	0.35	0.07	1.71	1.16
	(b) Diluted (In Rs.)	-0.11	0.07	0.11	0.35	0.07	1.71	1.16

NOTES:

- These financial results have been prepared in accordance with Indian Accounting Standards (Ind- AS) as prescribed under section 133 of Companies Act 2013 read with Rule 3 of the Companies (Indian Accounting Standards) Rules 2015 and relevant amendment thereafter.
- The above Financial results as recommended by the Audit Committee were considered and approved by the Board of Directors at their meeting held on 14-02-2022.
- The Financial results are subject to the Limited Review carried out by the statutory auditor's as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- The entire operations of the Company relate to only one segment. Hence, segmental reporting as per IND AS-108 is not made.
- The full format of the Quarterly un audited Financial Results are available on company's website and the stock exchange's website.
- Estimation uncertainty relating to the global health pandemic on COVID-19. The management has considered the possible effects, if any, that may result from the pandemic relating to COVID - 19 on the carrying amounts of trade receivables & inventories. In assessing the recoverability of receivables, the Company has considered internal and external information upto the date of approval of these financial results including credit reports and economic forecasts. The Company has performed sensitivity analysis on the assumptions used and based on current indicators of future economic conditions, the Company expects to recover the carrying amount of these assets. The impact of the global health pandemic may be different from that estimated as at the date of approval of these financial results and the Company will continue to closely monitor any material changes and future economic conditions.

FOR ORTIN LABORATORIES LIMITED
S.BALAJI VENKATESWARLU

S. Balaji Venkateswarlu
DIRECTOR
(DIN: 02010148)



Place: Hyderabad
Date: 14-02-2022



Independent Auditor's Review Report on Quarterly and Year to Date Unaudited Financial Results of Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

To

The Board of Directors of
M/s ORTIN LABORATORIES LIMITED

We have reviewed the accompanying statement of unaudited financial results of **M/s ORTIN LABORATORIES LIMITED** ('The Company') for the quarter ended 31st December, 2021 and for the period from 1st April, 2021 to 31st December, 2021. This statement is the responsibility of the company's management and has been approved by the board of directors. Our responsibility is to issue a report on these financial statements based on our review

We conducted our review of the Statement in accordance with the Standards on Review Engagement (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the entity' issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial results are free from material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly we do not express an audit opinion.

Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying statement, prepared in accordance with the recognition and measurement principles laid down in the applicable Indian accounting standards specified under section 133 of the Companies Act, 2013, read with relevant rules issued there under and other recognized accounting principles and policies has not disclosed the information required to be disclosed in terms of the regulation 33 of the SEBI (Listing Obligations and disclosure requirements) regulations, 2015 including the manner in which it is to be disclosed or that it contains any material misstatements..

For Sathuluri & Co
Chartered Accountants
Firm Reg No.006383S

(S.S.Prakash)
Partner
Membership No.202710



UDIN : 22202710ABYZTM9396

Place: Hyderabad
Date: 14/02/2022